Cancer NetworkOriginal article
<![CDATA[Dabogratinib Shows Early Activity in FGFR3-Altered Low-Grade NMIBC]]>
Phase 2positiveDabogratinibPositive
AI Analysis
Summary
Dabogratinib demonstrated early activity in Phase 2 SURF302 trial with 79% objective response rate in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer patients at 60 mg once-daily dosing.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
79% ORR with 60 mg once-daily oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC
Importance:6/10
Sentiment:
0.70
Phase 2OncologyNMIBCFGFR3Data Readout
Read the original article
Published by Cancer Network on September 10, 2026 4:06 PM